MedTrace Logo

Diagnostic Prediction of Pancreatic Masses

NCT06724055 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 110

Last updated 2024-12-09

No results posted yet for this study

Summary

The goal of this observational study is to learn if a strategy can be developed for differentiating autoimmune pancreatitis (AIP) and primary pancreatic lymphoma (PPL) from pancreatic ductal adenocarcinoma (PDAC) in patients presenting with pancreatic masses. The main question it aims to answer is:

What features, in the perspectives of clinical manifestation, laboratory tests, and imaging, can differentiate different kinds of pancreatic masses (AIP, PPL and PDAC)?

Participants will not be given any interventions since this is a retrospective observational study.

Conditions

  • Pancreatic Masses

Sponsors & Collaborators

  • Peking Union Medical College Hospital

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-01-01
Primary Completion
2023-05-31
Completion
2023-05-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06724055 on ClinicalTrials.gov